Protalix reports Q2 2026 results, reaffirms PRX-115 gout trial timeline and 2026 revenue guidance
Enrollment continues in the Phase 2 RELEASE study of PRX-115 with top-line data still expected in the second half of 2027, as the company reiterated full-year revenue guidance of $78.0 million to $83.0 million.
SEC filing